Kinnos Inc.

Kinnos Inc. is a US-based biotechnology company focused on infection prevention solutions, notably through its innovative product, Highlight®, enhancing the efficacy of disinfectants in healthcare settings. Founded in 2014 in Brooklyn, US, Kinnos Inc. specializes in infection prevention solutions.

The company was co-founded by Jason Kang, Katherine Jin, and Kevin Tyan, with Jason Kang serving as the CEO. Kinnos has successfully raised a total of USD 4. 54 mn through its Series A funding round, attracting investments from Kapor Capital, Partnership Fund for New York City, and Pioneer Healthcare Partners, which supports its valuation of USD 29. 18 mn.

Kinnos specializes in infection prevention solutions through its innovative product, Highlight®. This technology enhances the effectiveness of disinfectants used in healthcare settings by adding a visible blue color to standard disinfectant wipes, providing immediate feedback on surface coverage during cleaning. Highlight® is designed to work with commonly used disinfectant wipes based on bleach, quaternary ammonium compounds (quat), and hydrogen peroxide, allowing healthcare personnel to ensure thorough cleaning without disrupting existing workflows. Released in 2023, Highlight® has been implemented in high-risk infection areas such as Fraser Health and is widely utilized across various healthcare facilities in North America.

Kinnos generates revenue through direct sales of Highlight® to healthcare institutions, operating on a B2B model where healthcare facilities purchase Highlight® alongside their existing disinfectants. These transactions typically involve bulk orders, ensuring consistent supply in institutional settings. While specific pricing structures for Highlight® are undisclosed, its adoption is integral to the overall costs of disinfectant supplies used by healthcare providers, establishing Kinnos as a valued partner in infection prevention. Kinnos Inc.

plans to leverage its recent funding to further enhance its product offerings and expand into new markets. The company is focused on developing additional infection prevention solutions, with future product launches expected to complement Highlight®. Furthermore, Kinnos aims to penetrate broader healthcare markets across North America, enhancing its distribution capabilities. The latest round of funding will support these strategic initiatives, including potential collaborations with key players in the healthcare sector.